Press Release – New York, NY – August 20, 2025 – Sichenzia Ross Ference Carmel LLP represented Vyome Therapeutics, Inc., a company focused on developing drug products for currently unmet multifactorial inflammatory diseases like malignant fungating wounds, uveitis and inflammatory acne, in its recently closed merger with ReShape Lifesciences. Upon the closing, the company changed its name to Vyome Holdings, Inc. The post-merger company began trading on Nasdaq on Friday, August 15, 2025, and visited the Nasdaq MarketSite in Times Square, where its leadership team rang the Opening Bell and delivered remarks. SRFC partner Marcelle Balcombe attended the ceremony as well.
The SRFC team was led by partners Gregory Sichenzia and Marcelle Balcombe, with associate Nishkarsh Jakhar.
